Agenus’ Brain Cancer Vaccine Program Named a "Top Project to Watch" by Elsevier Business Intelligence

  Agenus’ Brain Cancer Vaccine Program Named a "Top Project to Watch" by
  Elsevier Business Intelligence

  *Agenus to present at 2013 Therapeutic Area Partnerships Conference

Business Wire

LEXINGTON, Mass. -- November 18, 2013

Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and
infectious diseases, today announced that its Prophage Series (HSPPC-96)
vaccine program for the treatment of brain cancer was selected as a 2013 Top
Project to Watch in oncology. This selection was made through Elsevier
Business Intelligence's panel of independent experts who screen hundreds of
programs and weigh their potential as future products.

The company also announced that Jennifer S. Buell, Ph.D., Vice President of
Clinical Research and Operations, will present an overview of the ongoing
Prophage Series vaccine Phase 2 program in newly diagnosed and recurrent
glioblastoma multiforme (GBM) at the 2013 Therapeutic Area Partnerships
Conference on Tuesday, November 19, 2013 at 1:10 pm EST at the Hyatt Regency
in Boston, MA.

A recent analysis from the Phase 2 trial in patients with newly diagnosed GBM
treated with Prophage Series in combination with the current standard of care
(radiation and temozolomide) showed an almost 18 month median progression free
survival, which represents a 160% increase versus current standard of care
alone.^1 Median overall survival (OS), the primary endpoint of the trial, is
23.3 months and remains durable in patients treated with Prophage Series
vaccine versus the standard of care alone, which is 14.6 months.^1 Patients
continue to be followed for survival. Based on these findings, Agenus plans to
hold an end of Phase 2 meeting with the US Food and Drug Administration to
discuss a Phase 3 trial that, if initiated and successful, could potentially
lead to marketing approval of the Prophage Series vaccine as a treatment for
patients with newly diagnosed GBM.

In addition to the Phase 2 newly diagnosed GBM trial, the National Cancer
Institute (NCI) is supporting a study of the Prophage Series vaccine in a
large, randomized Phase 2 trial in combination with bevacizumab (Avastin^®) in
patients with surgically resectable recurrent GBM. The study is being
sponsored by the Alliance for Clinical Trials in Oncology (ALLIANCE), a
cooperative group of the NCI. This trial is the largest brain tumor trial ever
funded by the NCI and the largest vaccine study ever conducted with Avastin.

The ALLIANCE trial is investigating the potential benefits of treatment with a
combination of Prophage Series and bevacizumab in a three-arm study of
approximately 222 patients with surgically resectable recurrent GBM using a
primary endpoint of OS. The study will compare efficacy of the Prophage Series
vaccine administered with bevacizumab either concomitantly or at progression,
versus treatment with bevacizumab alone. For additional information about the
ALLIANCE trial visit ClinicalTrials.gov using Identifier NCT01814813.

About Prophage Series Vaccines

Derived from each individual’s tumor, Prophage Series therapeutic vaccines
contain the ‘antigenic fingerprint’ of the patient’s particular cancer and are
designed to direct the body’s immune system to specifically target and destroy
cancer cells bearing this fingerprint. Prophage Series vaccines, based on
Agenus’ heat shock protein platform technology, are intended to leave healthy
tissue unaffected and limit the debilitating side effects typically associated
with traditional cancer treatments such as chemotherapy and radiation therapy.

Each patient’s cancer is unique. Random mutations and tens of thousands of
genes mean even within the same type of cancer, no two individuals’ cancers
are biologically the same. Taking these factors into account, the Prophage
Series vaccines are developed from the best biological representation of a
patient’s cancer and created individually for each patient from their own
tumor.

The Prophage Series vaccines are currently being studied in both newly
diagnosed and recurrent GBM. GBM is the most aggressive primary malignant
brain tumor and accounts for the majority of diagnoses of malignant cancers of
the brain.

For more information about Prophage Series vaccines and Agenus’ heat shock
protein platform, please visit http://agenusbio.com/science/prophage.php.

About Agenus

Agenus Inc. is a biotechnology company developing treatments for cancers and
infectious diseases. The company has multiple immunotherapeutic products based
on strong technology platforms that are advancing through the clinic. Agenus’
technology is further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical trials with
corporate partners. For more information, please visit www.agenusbio.com.

About Elsevier Business Intelligence and the Therapeutic Area Partnerships
Conference

Elsevier Business Intelligence provides business intelligence on regulatory,
business and reimbursement issues that are vital to the healthcare industry.
Through a range of products including publications, conferences, databases and
reports, Elsevier Business Intelligence places biopharma and medical device
professionals, and those who focus on these industries, at the forefront of
knowledge, by providing a combination of news and information together with
penetrating insight and analysis.

Organized by Elsevier Business Intelligence, the 2013 Therapeutic Area
Partnerships (TAP) conference is designed to bring together biopharmaceutical
industry decision makers to assess the most promising drug programs available
for partnering in the following therapeutic areas: oncology,
cardiovascular/metabolic diseases, neuroscience, infectious diseases,
anti-inflammatory/autoimmune diseases and advanced therapies. For more
information, please visit the conference website at
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.

Forward-Looking Statement

This press release contains forward-looking statements, including statements
regarding clinical trial activities, the publication of data, and the
potential application of the Company’s technologies and product candidates in
the prevention and treatment of diseases. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission for the period ended
September 30, 2013. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus undertakes
no obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement. Agenus’ business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus’ business and
securities, investors should give careful consideration to these risks and
uncertainties.

References

1. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N
Engl J Med, 2005. 352(10): p. 987-96.

Contact:

Media and Investor:
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and Corporate Communications
jonae.barnes@agenusbio.com
 
Press spacebar to pause and continue. Press esc to stop.